This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Moderna (MRNA) to File EUA for Use of mRNA-1273 in Children
by Zacks Equity Research
Moderna's (MRNA) COVID-19 vaccine, mRNA-1273, generates robust neutralizing antibody response in a phase II/III study evaluating it in children.
Novavax's (NVAX) COVID Jab Gets EUA Nod for Kids in India
by Zacks Equity Research
Novavax's (NVAX) COVID-19 vaccine receives its first authorization for emergency use in adolescents aged 12 years and above in India.
Biotech Stock Roundup: BMY's Drug Approval, MRNA's Vaccine Update & More
by Zacks Equity Research
Pipeline and regulatory updates from Bristol Myers (BMY) and Moderna (MRNA) are a few key highlights from the biotech sector during the past week.
Target Hospitality and Big Lots have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Target Hospitality and Big Lots have been highlighted as Zacks Bull and Bear of the Day
Pfizer (PFE) Recalls Hypertension Drug Due to Impurities
by Zacks Equity Research
Pfizer (PFE) is recalling six lots of Accuretic tablets, one lot of quinapril and hydrochlorothiazide tablets and four lots of quinapril HCl/ hydrochlorothiazide tablets.
FDA Panel to Discuss Fourth Booster Dose in April Meeting
by Kinjel Shah
The FDA advisory committee meeting on Apr 6 is likely to give an insight into how the regulatory agency feels about the need for additional boosters of COVID-19 vaccines.
The Zacks Analyst Blog Highlights Invesco QQQ, JD.com, MercadoLibre, Moderna, DocuSign, and Baidu
by Zacks Equity Research
Invesco QQQ, JD.com, MercadoLibre, Moderna, DocuSign, and Baidu have been highlighted in this Analyst Blog.
Moderna (MRNA) Up on FDA Filing for Second COVID Booster Jab
by Zacks Equity Research
Moderna (MRNA) seeks the FDA's authorization for a fourth dose of its COVID vaccine in adults who already got an initial authorized booster dose of the same in the United States.
5 Stocks in Nasdaq ETF That Gained Most Last Week
by Sweta Killa
The Nasdaq Index logged in the best weekly gain since November 2020 fueled by the Fed¿¿¿s decision to raise interest rates for the first time since 2018 and progress in the Russia-Ukraine peace talks
The Zacks Analyst Blog Highlights J&J, Pfizer, BioNTech, and Moderna
by Zacks Equity Research
J&J, Pfizer, BioNTech, and Moderna have been highlighted in this Analyst Blog.
What's in Store for J&J's (JNJ) Segments & Pipeline in 2022?
by Zacks Equity Research
J&J's (JNJ) Pharma unit is performing above market levels. The Consumer unit is improving. The Medical Devices unit is being hurt by soft recovery trends in medical procedures.
Moderna (MRNA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Moderna (MRNA) closed at $168.26 in the latest trading session, marking a -0.65% move from the prior day.
Moderna (MRNA) Up More Than 30% in 10 Days: What Lies Ahead?
by Zacks Equity Research
Moderna's (MRNA) shares are rising presumably in anticipation of rising demand for its COVID-19 vaccine amid authorization for younger population and the fear of another global infection wave.
Biotech Stock Roundup: NKTR Plunges on Study Failure, MRNA Offers Updates & More
by Zacks Equity Research
Pipeline and regulatory updates from Nektar (NKTR) and Moderna (MRNA) are a few key highlights from the biotech sector during the past week.
Pfizer, BioNTech Seek FDA Nod for 4th COVID Shot in Older Adults
by Zacks Equity Research
Pfizer (PFE) and BioNTech (BNTX) believe that for individuals to be adequately protected, additional booster doses of COVID vaccines are needed.
China's COVID-19 Lockdown Brings Back Focus on Healthcare ETFs
by Sweta Jaiswal, FRM
Let's take a look at some healthcare ETFs that are regaining popularity among investors as COVID-19 cases rise in China.
BioNTech (BNTX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On BioNTech's (BNTX) fourth-quarter earnings call, investors' focus is expected to be on the sales performance of Comirnaty, its COVID-19 vaccine developed in partnership with Pfizer.
Moderna (MRNA) Early-Stage HIV Vaccine Study Begins, Stock Up
by Zacks Equity Research
Moderna (MRNA) starts dosing in an mRNA-based HIV vaccine study.
Moderna (MRNA) Stock Jumps 8.6%: Will It Continue to Soar?
by Zacks Equity Research
Moderna (MRNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Moderna (MRNA) Stock Moves -0.95%: What You Should Know
by Zacks Equity Research
In the latest trading session, Moderna (MRNA) closed at $138.20, marking a -0.95% move from the previous day.
Moderna (MRNA) Starts Omicron-Specific Bivalent Booster Study
by Zacks Equity Research
Moderna (MRNA) administers the first dose in the phase II study of its Omicron-specific bivalent booster candidate (mRNA-1273.214). It expects to enrol 375 subjects for the same in the United States.
Ocugen (OCGN) Down 23% With FDA Denial of COVID Vaccine EUA
by Zacks Equity Research
The FDA turns down an emergency use authorization request from Ocugen (OCGN) to use its COVID-19 vaccine Covaxin in pediatric population. Stock depreciates.
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for IBB
Thermo Fisher (TMO) Extends Collaboration With Symphogen
by Zacks Equity Research
Thermo Fisher's (TMO) recent extension of collaboration with Symphogen is intended to support biopharmaceutical discovery and development.
The Zacks Analyst Blog Highlights Moderna, Gilead Sciences, Kodiak Sciences and Lexicon Pharmaceuticals
by Zacks Equity Research
Moderna, Gilead Sciences, Kodiak Sciences and Lexicon Pharmaceuticals have been highlighted in this Analyst Blog.